Home » Topics » BioWorld Science

BioWorld Science
RSS

Cyxone to seek clearance for phase I study of MS drug candidate T20K

May 24, 2019

NIAID begins phase I/II study of RSV vaccines in children aged 6-24 months

May 24, 2019

SBIR grant supports Sentia's development of astressins for IBS

May 24, 2019

Synlogic enters collaboration with Roche to study SYNB-1891 with Tecentriq in advanced tumors

May 24, 2019

Bioimics identifies bacterial ribonuclease P inhibitors

May 24, 2019

FDA grants marketing authorization to Zika virus diagnostic test

May 24, 2019

U.S. researchers present ALDH1A1 inhibitors

May 24, 2019

GlaxoSmithKline identifies IDO1 inhibitors

May 24, 2019

Norovirus VLP vaccine TAK-214 immunogenic, well tolerated in phase II study

May 24, 2019

Amgen discloses APLNR agonists

May 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....